Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Huge opportunity for $IMUN starting next year. I will do DD on Sunday about the $CBLI & IMUN
Today is CBLI annual meeting, hopefully they approve the merger
October call
I listened to the conference call and Michael mentioned you have pre clinical positive data on covid19. It seems to me they have done some preclinical trial for covid19
Nice ??
$EMOR financial report
12. Subsequent Events.
On 1/02/2020 - Emerald gained exclusive worldwide development rights from Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS), to ESS, MANF and PhenoGuard FDA regulated therapeutics with Amarantus to receive Emerald preferred stock valued at a minimum of $66.6 million.” 33M shares of $EMOR will be issued to $AMBS
$imun & Cytocom COVID 19 phase 2 trial slide on Twitter
I put buy order of 140K at .0147
Lol WTF I didn't asked you the question.
He needs to answer the real questions about convertible debt that is keeping stock price below .10. His tweets don't mean shit if he doesn't address convertible debt right away.
Customer review “My family and I were directly exposed to CV19 a few weeks ago, we had just started taking Tollovid and no one in my family contracted it while the other family we were with all ended up positive and sick. While there is no way of proving it was because of taking Tollovid”
I don’t have premium account to respond privately. Very bullish on the company. The COVID 19 trial could be announced any day. Also Imun is perfect target acquisition for reverse merger by privately held company.
$TOMDF Commercial Launch
Tollovid Immune Sup $175 per bottle
This groundbreaking proprietary blend of herbs and advanced 3cl protease
$igen $cbbt $cbbt $nspx $htbx $aytu $codx #Pennystocks $ibio $hgen $cydy $aytu $srne $abt #OTCMarkets #OTCStocks
https://t.co/Nynum8sPdP
I'm not negative at all. Why would anybody without any interest bashes the company every single day. If you think the company is garbage go invest to another company. Its so fucking boring reading your posting.
I don't understand why you keep posting shit. If You don't like the company move on.
Not you , I heard some people whistleblowers already Know about this ! ? Know what spelled out
Lol I'm not promoting anything? Why would I waste my time to promote.
Everyone else got there’s for free ?
You are clueless about penny stock companies. How do you expect raising money ??? No investor will invested unless the deal are favorable to them. Look at MRNA was dilution machine over 400M OS, before covid 19. Now the company market cap jumped from 6B to 60B in 8 months. Here is another one for you cydy 570M, OS, current mcap over 1B.
$TOMDF @G_Commish now is your chance to shine
Diagnostics M&A has increased tremendously recently:
cancer-detection company Grail acquired by
@illumina for $8B 09/22/202)
multi-cancer screening testing Thrive Earlier dect corp acquired by @ExactSciences for $2.15B) 10/2020
Come on man! 2 million shares is not a big dilution. He has built a billion platform.
I have tweeted in Twitter about this company. Ej23ny
We both have similar numbers except my revenue projection is higher 50M-100M by 2021-2022
Twitter ej23ny
I said should acquire and biib focus is in autoimmune, inflammatory, infectious diseases. Merck just acquired private company for 2.7b
I know. It’s mind boggling to me that biib is acquiring cyto now before the merger. 3B valuations would be fair deal & Imun would get 450M, 100M should be paid as dividend & the rest should used to acquire new assets &pay the debt
You too. Good luck to you
Any company acquired imun gets the equity stakes on cytocom which could be huge and easier for private companies to become public instead going through ipo process which is very expensive & take long time. Look at some reverse mergers $MDGL current price over $120, MDVN came through reverse merger & acquired for 14B
I agree with everything you mentioned. The company is tremendously undervalued and I believe the logical solution is imun should be acquired by cytocom or another private company. The Crohns & covid 19 market size is between 32-35B, huge opportunities for any company acquired imun.
Very funny you actually act that you know about trials design. Venclexta was approved based on phase 1B non randomized trial, 114 patients enrolled. The overall survival was not even listed as secondary endpoint.
I’m so amazed reading your misleading post. The secondary endpoint doesn’t effect the filing of BLA. Also if the company resigned the trial 8k form must be filed.
Right about what
Look at 10Q report filed 11/16, you will see the 15% equity stake cytocom
The valuation for combined companies is between 2-3B, and imun could be valued 180M-270M
Thanks. I'm very bullish on the company but you have to be patient until the merger gets completed. 4 phase 3 trials planned & phase 2 covid19. Tremendous opportunities for all companies.
Okay. Good luck
I don't think you understand. I already explained to you the cytocom value is recorded as percentage. The cytocom assets have no $ value and cannot be reported on balances sheet. After the merger gets approved than equity state is going to be reported as $ amount.
Off course buy out will come after the merger. It could be at least 2B+
Is the same shit. Cytocom is private company and the stock have no value because the stock is not traded on national exchange. Why are you making it big deal. When the merger gets completed the company will report the shares on the balance sheet.
No man! Imun cannot force cytocom to do 3rd party valuation. You only do 3rd party valuation if filed for IPO or sell assets. The equity stake must be reported as percentage.
I agree with Kevin. How could you report cytocom shares if the company is privately held & no 3rd party valuation. The transaction could only be reported on the foot note.